Triple-Pronged attack on lung cancer: aspirin, smoking cessation, and lifestyle changes tested in new trial
NCT ID NCT03654105
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of low-dose aspirin, a smoking cessation drug called cytisine, and guidance on diet and exercise can reduce chronic inflammation and lower lung cancer risk in heavy smokers aged 55 to 75. The 2000 participants will also receive annual low-dose CT scans for early detection. The goal is to see if this multi-pronged approach can lower inflammation levels and help people quit smoking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose aspirin (acetylsalicylic acid) and cytisine (a smoking cessation aid)
What this could lead to
If it works, this could point toward a practical combination of lifestyle changes and medication to lower lung cancer risk in long-term smokers.
What could go wrong
This is a mid-stage pilot study with 2000 participants, so results are not definitive. The benefits may be small, and aspirin can cause bleeding or stomach issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy